Steven Erpelinck BSc. MBA
- bioavailability
- microdosing
- AMS transporters
- permeability
- PBPK modeling
Event
Metabolite identification in Phase 1 via microtracer AMS
San Diego, Ca | Hilton San Diego Resort & Spa • 17 Sep 2017 - 19 Sep 2017
Developing a new drug is a lengthy, expensive process. The earlier information concerning efficacy and safety of a candidate drug in humans is available, the better. Microdosing enabled by a biomedical Accelerator Mass Spectrometer (AMS) supports this process. At the ACCP in San Diego, September 17-19, TNO will present its microdosing/microtracer AMS capabilities.
We will also show our in vitro microbiota screening platform I-screen which can be used in preclinical phase to measure and identify microbiota induced 'human' metabolites.
A microdosing AMS study requires a very low dose (< 100ug), reduces costs, shortens the development process and ensures a reduction of lab animals during preclinical development. TNO is the only organisation in Europe with an auto-combustion based biomedical Accelerator Mass Spectrometer (AMS) that enables this research.
A flavor of microdosing AMS based applications
- Absolute BA studies
- MIST
- Mass Balance
- Pediatric microdosing
- Half-life of Biologics
- Screening of Antibodies/ADC's
- Biosimilars
At the ACCP, TNO will present its capabilities in the field of microdosing AMS studies showing that these studies may accelerate and de-risk drug development. Advantages of our auto-combustion based AMS in comparison to the conventional graphitisation based AMS will be demonstrated. We look forward to meeting you at our booth, number 202.
See also
Our work
Microtracer AMS: Accelerate your clinical development
De-risk and accelerate drug development with TNO’s exclusive auto-combustion-based AMS technology. Each Phase I, first-in-human (FIH) study can be a MIST and Mass Balance study, for faster, economical... Read more
Roadmap